A Heart Rate Monitoring App (FibriCheck) for Atrial Fibrillation in General Practice: Pilot Usability Study

Simon Gabriël Beerten¹, MD, MSc; Tine Proesmans², MSc; Bert Vaes¹, MD, PhD
¹Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
²Qompium, Hasselt, Belgium

Corresponding Author:
Simon Gabriël Beerten, MD, MSc
Department of Public Health and Primary Care
KU Leuven
Kapucijnenvoer 7 blok h - bus 7001
Leuven, 3000
Belgium
Phone: 32 16194050
Email: simon.beerten@kuleuven.be

Abstract

Background: Atrial fibrillation (AF) is a major risk factor for stroke. The current opportunistic screening procedure consists of pulse palpation and an electrocardiogram when an irregular rhythm is found. Smartphone apps that measure heart rhythm could be useful in increasing the detection of AF in a primary care setting.

Objective: We conducted a pilot study with the smartphone app FibriCheck to assess whether the introduction of such an app is feasible.

Methods: Four general practices across Flanders provided patient data for the study. Inclusion criteria for participants were aged 65 or older and a CHARGE-AF score of at least 10%. We excluded patients with known AF or a pacemaker. Participants were asked to measure at least twice a day with FibriCheck (for at least 14 days). They were provided the 36-Item Short Form Survey (SF-36) questionnaire both before and after the study, as well as different surveys concerning their user experience and general perception of technology.

Results: There were 92 participants (36 women and 56 men). The study population was relatively homogenous concerning risk factors and medication use at baseline. During the study period, 5/86 (6%) participants were found to have AF (6 dropouts). The average study period was 23 days and the average number of measurements per day was 2.1. Patient compliance was variable, but high. On the whole, there were no appreciable changes in quality of life. The overall user experience and satisfaction were very high.

Conclusions: FibriCheck is a relatively easy-to-use smartphone app to complement AF screening in primary care. Its implementation in this setting is certainly achievable, and one can expect high rates of patient compliance. Based on these results, a planned cluster randomized trial will be going ahead.

Trial Registration: ClinicalTrials.gov NCT03509493; https://clinicaltrials.gov/ct2/show/NCT03509493

(JMIR Form Res 2021;5(4):e24461) doi: 10.2196/24461

KEYWORDS
atrial fibrillation; smartphone app; FibriCheck; primary care

Introduction

Atrial fibrillation (AF) has long been known as an independent risk factor for stroke [1]. It is highly prevalent among older patients in primary care, and the incidence is seemingly on the rise [2,3]. Hospitalizations for stroke are an important financial burden to the society, so a strategy for early and cost-effective screening interventions seems useful [4]. Current best clinical practice points to an opportunistic screening approach to detect AF, in which at-risk patients undergo routine pulse palpations and electrocardiograms (ECGs) when an irregular rhythm has been found [5,6]. Screening appears to be most cost-effective when done from age 65 [7]. Taking an ECG in routine general practice, however, is quite time-consuming. Furthermore, given
the sometimes paroxysmal nature of AF, it could be missed by an opportunistic screening method during a routine consultation [8]. A significant proportion of these patients remain undiagnosed [9]. Holter measurements and event recorders could partially remedy this issue, but interpretation is again very time-consuming and unlikely to be very cost-effective [10].

Portable heart rate monitoring devices have recently been introduced to provide an on-the-go way to check for arrhythmias in general practice [11]. They could provide a convenient add-on to current opportunistic screening. Since the advent of smartphones, efforts have been made to use the phone’s built-in camera to register heart rhythm via photoplethysmography [11,12]. Today, various smartphone apps are available [11,13,14], and they all perform well in terms of diagnostic accuracy and yield [15] and appear to be cost-effective [7].

In Belgium, the Hasselt-based firm Qompium has developed one such smartphone app named FibriCheck. The diagnostic accuracy of this app has already been studied previously [16]. An upcoming cluster randomized controlled trial will study its efficacy as a diagnostic tool to facilitate screening. This pilot study aimed to assess the ease of use and implementation of the FibriCheck app in a primary care setting.

**Methods**

**Recruitment**

**Practices**

This feasibility study ran from June to December 2017. Four general practices across Flanders were recruited in this study (Table 1). Every practice used different medical software to code diagnoses and parameters: a deliberate choice to test the ease with which data could be derived from each software package. Each practice was asked to include around 20 patients.

**Table 1.** Overview of recruiting practices.

| Name of the practice                  | Place                      | Team                  | Medical software       |
|---------------------------------------|----------------------------|-----------------------|------------------------|
| Huisartsencentrum Millegem           | Mol, Antwerp               | 4 GPs, 4 trainees     | MediDoc                |
| Groepspraktijk Hoëilaart              | Hoëilaart, Flemish Brabant | 6 GPs, 2 GP trainees  | CareConnect            |
| Huisartsenpraktijk Keerbergen         | Keerbergen, Flemish Brabant| 2 GPs, 1 GP trainees  | Windoc                 |
| Praktijk Gilissen                     | Riemst, Limburg            | 2 GPs, 1 GP trainees  | Prodoc                 |

aGP: general practitioner.

**Participants**

We opted to only include patients at high risk for AF to test the suitability of the FibriCheck app. We only included the older population, as AF is more prevalent in this group and they would therefore benefit the most from this intervention. There was no control group. The 5-year risk of AF is commonly indicated using the CHARGE-AF score [17]. This score was calculated manually for each potential participant, by extracting the necessary data from the patient file. Frailty score was calculated according to Tocchi et al [18]. A score of 0 means no frailty, a score of 1-3 means increased risk of frailty, and a score of 4 or more indicates definite frailty.

We opted to exclude patients already on anticoagulants (the mainstay of treatment for AF with higher cardiovascular risk), as this screening intervention would probably not lead to any relevant change in treatment for that population.

The inclusion criteria were (1) a CHARGE-AF score of 10% or more and (2) aged 65 or older. Exclusion criteria were (1) known or already diagnosed AF (including known paroxysmal AF), (2) patient has a pacemaker, (3) patient takes oral anticoagulants, and (4) patient is unable to use a smartphone app due to physical, visual, or cognitive impairment.

Upon selection, participants were asked to sign a consent form to be included in the study.

Participants were given a unique coded account number, which is linked to the specific FibriCheck app on their smartphone. Smartphones were provided in case participants did not own one themselves; others just had to install the app.

At recruitment and at the end of the study, an ECG and a FibriCheck measurement were taken.

The time the physician spent to explain the study to the participants and on educating them how to use the FibriCheck app was registered.

In addition, physicians were asked to indicate what they would have done if the FibriCheck app was not available (ie, if they were not included in the study). There were 2 options: no action (and wait for the patients to consult on their own) or advise a follow-up consultation. Physicians could also indicate what exactly they would have done without the availability of the app, and how many consultations they normally anticipated during a 1-year period.

**Measurements**

The FibriCheck app uses the smartphone’s built-in camera to measure the heart rate. The users are instructed to place their finger on the camera and wait for 60 seconds as a measurement is taken, preferably in the seated position with the arm resting.

At the start of the study, participants were asked to measure at least twice a day with the FibriCheck app and to indicate if they experienced any symptoms preceding the measurement. The minimum required measuring period was 2 weeks; the individual participant’s study period ended after a maximum of 4 weeks. Patients were considered incompliant and excluded when there...
were no measurements for 2 weeks or more during the study period, or if they were lost to follow-up.

After measuring, the FibriCheck app reviewed every measurement immediately afterward, with 4 possible outcomes: normal measurement (no tachycardia, no extrasystole, no irregular rhythm; indicated in green), inadequate signal (indicated in blue), measurement requiring urgent attention (possible AF; not signaled to participants in the context of this pilot study), and warning (usually more than 4 extrasystoles, or bradycardia or tachycardia: indicated in orange). Participants were also able to indicate their stress levels with each measurement. The score ranged from 0 (low stress) to 10 (highest stress) with step intervals of 2.5.

**Quality of Life**

Patients were asked to fill in the 36-Item Short Form Survey (SF-36) questionnaire, to get an impression of their quality of life at baseline. This survey contains 36 questions from various health domains, such as physical functioning or emotional health [19]. It uses graded responses: answers corresponding to more favorable health states receive higher scores (the minimum and maximum being 0 and 100, respectively). The scores for the questions on a specific health domain are then averaged to compile a subtotal score. Each participant was asked to complete the questionnaire again at the end of the study period. The SF-36 questionnaire has been validated for use in general practice [20]. We used the Dutch translation in this study [21].

**Technology Perception—App Usability**

Participants were provided questionnaires at the beginning of the study, concerning their perception and familiarity of current technology. At the end of the study, a general questionnaire about their use of the FibriCheck app was provided. Answers were graded on a 5-step scale, ranging from “completely disagree” to “fully agree.” These questionnaires were created by the authors and were not validated previously.

**Statistical Analysis**

A 2-proportion, 2-tailed Z test was used to analyze the difference in risk factors and medication between male and female participants in the study. To compare the scores on the various domains of the SF-36 questionnaire, we used a 2-tailed Wilcoxon signed-rank test, as we did not assume normality. The value for any missing item was imputed as the mean value for nonmissing items.

We refrained from calculating the total average score of the SF-36 questionnaire. This is often done to form an idea about the general health of study participants. However, this supposes a 50/50 equilibrium between the mental and physical aspects of health, and this practice is generally discouraged [22].

The minimal clinically important difference for the health-related SF-36 questionnaire was calculated according to earlier studies for similar populations [23,24]. We used a distribution-based method, as an anchor-based method was not feasible for this pilot study. A cut-off value of 1 standard error of measurement (SEM) was used to define a meaningful improvement or deterioration, in line with previous studies [24].

The following formula was used to calculate the SEM, with $\sigma$ being the SD of a particular test and $r$ the reliability coefficient or Cronbach alpha of the same test [23]:

$$\sigma\sqrt{1-r}$$

Data for this formula, as applicable to the SF-36 questionnaire, were gathered from the Medical Outcomes Study [25].

The answers to the questionnaires concerning technology perception and usability of the FibriCheck app were weighted according to importance: for instance, “completely agree” (or a similar answer) was assigned a value of 2, “agree” a value of 1, “completely disagree” a value of −2, and so on.

For other data, we used descriptive statistics throughout.

**Ethics Approval**

This pilot study was approved by the Ethical Committee of Hospital Zuid-Oost Limburg (Genk, Belgium) on June 6, 2017 (registration number B371201731704).

**Results**

**Participants**

A total of 92 participants were recruited from the 4 practices listed in Table 1: (1) Huisartsencentrum Millegem (17 patients), (2) Groepspraktijk Hoeilaart (35 patients), (3) Huisartsenpraktijk Keerbergen (20 patients), and (4) Praktijk Gilissen (20 patients).

There were 36 female and 56 male participants in the study population. The mean age was 78 (SD 8.1; range 45-94 years). Ultimately, we did include 4 patients under 65 who met the other inclusion criteria. The rest of the population was 65 or older. The mean BMI was 28.1 kg/m² (SD 4.6; range 17.3-42.7 kg/m²). In our study population, the mean frailty score was 2.6 with 21/92 participants (23%) having a score of 4 or more.

Before the study commenced, participants were asked whether they had used a smartphone before or had the ability to use a smartphone correctly. There was a response rate of 96% (88/92 participants). In total, 16% (14/88 participants) had a smartphone and knew how it worked, 32% (28/88 participants) did not have an idea of what to do with a smartphone, 13% (11/88 participants) had used a smartphone before and could manage, while 40% (35/88 participants) had used a smartphone but found they needed help.

At recruitment and at the end of the study, an ECG and a FibriCheck measurement were taken. Before commencement, 93% of participants (86/92) were in sinus rhythm, 6% (5/92) had ectopic beats, and 1% (1/92) had atrial flutter.

On average, physicians spent around 15 minutes to get participants started with the smartphone and the app (range 5-40 minutes), and another 21 minutes to fill in the necessary administrative paperwork (consent forms, patient education leaflets, etc.; range 10-40 minutes).

The risk factors of the participants, as well as the different medications they were taking at baseline, are listed in Multimedia Appendix 1.
Physicians would have chosen the “wait and see” approach for 67/92 patients (73%), if the FibriCheck app would not have been available. In this scenario, they anticipated on average between 2 and 3 consultations over a 1-year period. The mean CHARGE-AF score for participants in the “follow-up” group was 20.89, whereas that in the “wait and see” group was 18.60.

**Measurements**

There were 24 consultations with 18/92 patients (20%) purely because of a FibriCheck finding, as well as 3 hospital admissions (3%) indirectly resulting from a finding on the app. All the aberrant rhythms detected during and at the end of the study are summarized in Table 2.

The average participant study period was 23 days. Participants conducted an average of 49.5 measurements during that time, which amounts to 2.1 measurements per day. Figure 1 shows the average number of measurements for each participant as a line. The “2 measurements per day” criterion is highlighted, which gives an idea about participant compliance.

### Table 2. Rhythms detected during the study (N=86).\(^a\)

| Heart rhythm                   | Value, n (%) |
|-------------------------------|-------------|
| Ectopic beats (SVES\(^b\)/VES\(^c\)) | 10 (12)     |
| Tachycardia                   | 2 (2)       |
| Atrial fibrillation           | 5 (6)       |

\(^a\)Six dropouts: 4 exclusions by patient request, 2 excluded due to incompliance.  
\(^b\)SVES: supraventricular extrasystoles.  
\(^c\)VES: ventricular extrasystoles.

**Figure 1.** Average number of measurements per day, per participant.

A total of 4489 validated measurements were taken for 90 participants in total. Approximately 71% of participants (64/90) had 2 or more measurements per day. A summary of the most common symptoms accompanying the measurements is displayed in Figures 2 and 3. Most measurements did not report a symptom and for each measurement multiple symptoms could be reported. There were a total of 3313 measurements that had a stress level registered. The mean stress level was 2.29.
Quality of Life
In total, 54 participants filled in the SF-36 questionnaire at the start of the study. We excluded 4 patients from the final analysis, because they failed to complete the questionnaire at the end of the study. Multimedia Appendix 2 shows the results for the 50 participants who completed the questionnaire.

Technology Perception and App Usability
The data on the technology perception, gathered at the beginning of the study, and the data on the use of the FibriCheck app, are summarized in Multimedia Appendix 3. The specific questions belonging to each category, together with their weighting, can be found in Multimedia Appendices 4 and 5. Results are weighted according to the different response categories: more positive or more negative responses are thus weighted accordingly. For purposes of readability, we did not plot the neutral answers. The response rates for the technology and FibriCheck surveys were 89% (82/92 participants) and 77% (71/92 participants), respectively.

Participants were most satisfied with the following aspects of the app: simplicity (52/71, 73%), on-the-go heart rhythm analysis (52/71, 73%), and the possibility to be followed remotely (48/71, 68%).

Discussion
Principal Findings
This pilot study concerned the ease of use and implementation of the AF case-finding app FibriCheck in primary care. The study population was rather homogenous, and smartphone familiarity at baseline was relatively poor. We found a high measurement compliance, with most participants finding the app easy to use. AF was detected in 5/86 participants (6%). Overall, the user experience was positive, and most participants agreed the app gave them a feeling of reassurance and could benefit their doctor–patient relationship.

Participants
This pilot study merely focused on the feasibility of the introduction of an AF case-finding app in a primary care setting. As we were testing the app itself rather than its effect on the detection rate of AF, we did not add a control group and focused only on those patients we thought would benefit the most from such an app.

The study population of 92 participants was predominantly male, but there were no differences between men and women regarding risk factors and medication use at baseline. However, the proportion of men with a history of thrombosis or peripheral vascular disease was significantly greater ($P=.02$ for both).
addition, our study population was generally overweight, so it might not be representative of the average general practice population.

Smartphone familiarity was rather poor in our study. Use of smartphones does tend to be lower in older populations, for reasons such as a lack of interest in current technologies, visual impairments, or financial problems [26]. However, most participants in our study had no problems using the FibriCheck app. There was some preliminary work involved in acquainting participants with the app, which took around 15 extra minutes in our study. This is not extraordinary, though quite significant in the daily schedule of a general practitioner.

**Measurements**

An important feature of this pilot study was patient compliance. As this was a preliminary study in anticipation of a larger cluster randomized trial, we set the bar for noncompliance quite low: only participants with no measuring activity for 2 weeks or more were excluded from the study.

The 2-week mark proved easy to reach: the average study period was 23 days. This timeframe was chosen deliberately, as 14 days seem to be a sufficient time to detect most AF cases [27]. The average number of measurements per day was 2.1, with a large spread (Figure 1). Around 71% (64/90) of participants measured twice a day or more. Methodologically similar studies found compliance rates ranging from 75% to 95% [13,27], whereas in another study the measurements were performed in the presence of a trained personnel [14].

The proportion of participants with AF in this study was 6% (5/86), higher than other comparable studies or the general population [13,27,28], most likely because we only included high-risk patients and possibly because of the effect of screening. Another device study [14] differed in the study design, which makes comparison difficult. The most indicated symptoms when conducting a FibriCheck measurement (if there were any) were fatigue and palpitations, in line with findings from a similar study [13].

**Quality of Life**

We asked participants to complete the SF-36 questionnaire both before and after the study, to see if there were any appreciable changes in quality of life. There were no changes in any of the SF-36 health domains, except for Emotional Well-being, which showed a significant decrease (P<.001). This could be due to any number of factors: added stress due to the enrollment in the study in general, or anxiety because of preoccupation with heart disease in particular, possibly amplified by having to test the heart rhythm at least twice a day. Patient anxiety could potentially be diminished when the device does not give direct feedback about the results, as in an ECG app [13].

**Technology Perception and App Usability**

The participants in our study were very accepting of the current technology and very open to try the FibriCheck app, as most could see its benefit if data protection was properly ensured. Another study found that technology acceptance among the elderly seems to be increasing, provided certain barriers (privacy issues and design) are well taken care of [29]. The FibriCheck app was found to be easy to use, and it gave most participants a feeling of reassurance and safety. They also believed it improved their doctor–patient relationship.

**Strengths and Limitations**

This was the first study to assess the feasibility of integrating the FibriCheck app in a primary care setting. The study population was sufficiently homogenous to be able to draw some relevant conclusions. There was no control group, as this was merely a feasibility study. A comparison with routine care was thus not possible.

Overall, there were varying amounts of missing data, though generally not very much (up to 4.0% [26/644 data points] for the demographic data) and at acceptable levels for the different surveys. We decided to ignore missing data when reporting descriptive statistics but opted for mean value imputation in the surveys.

**Conclusions and Implications for Practice**

Integrating a smartphone app such as FibriCheck in primary care seems to be an easy way to complement routine screening. We found high rates of patient satisfaction, reassurance, and compliance. Smartphone familiarity might still be an issue, although most participants of this study had no problem using the app.

The findings in this study pave the way for the routine use of new technology in a general practice setting. Given the widespread use of smartphones, screening apps could be a cost-efficient way of complementing routine care with smart technology. Apps like FibriCheck could potentially increase AF detection in general practice, compared with traditional screening, decreasing the burden of associated morbidity and mortality. As technology acceptance among the elderly will continue to increase, so will the relevance of screening apps.

Cost–benefit issues and potential barriers to large-scale implementation have yet to be identified.

A cluster randomized trial, to compare the diagnostic yield of FibriCheck with usual care, is planned (ClinicalTrials.gov NCT04545723). In short, the results of this pilot study indicate that the implementation of a smartphone screening app in general practice is easy and feasible, which could guide future trials by shifting the focus away from practical issues, toward the specifics of screening and diagnosis.

**Acknowledgments**

This study was funded by Qompium (based in Hasselt, Belgium), the developer of the FibriCheck app. They also provided technical assistance and smartphones for participants who did not have one. Study data are available for extraction from their servers.
Authors’ Contributions
SB wrote the manuscript and performed final statistical analyses. BV conceived the study design and assisted in writing. TP participated in data extraction, collection, and analysis. All authors proofread the final manuscript.

Conflicts of Interest
TP is an employee of Qompium, the study’s funder. Other authors declare no conflicts of interest.

Multimedia Appendix 1
Risk factors and medication of participants at baseline, for men and women.
[PDF File (Adobe PDF File), 139 KB-Multimedia Appendix 1]

Multimedia Appendix 2
Comparison of SF36 domain scores, at start and end of study (N=50).
[PDF File (Adobe PDF File), 94 KB-Multimedia Appendix 2]

Multimedia Appendix 3
Questionnaires concerning technology perception and FibriCheck usage.
[PDF File (Adobe PDF File), 94 KB-Multimedia Appendix 3]

Multimedia Appendix 4
Technology perception questionnaire with weighting.
[PDF File (Adobe PDF File), 98 KB-Multimedia Appendix 4]

Multimedia Appendix 5
FibriCheck usage questionnaire with weighting.
[PDF File (Adobe PDF File), 106 KB-Multimedia Appendix 5]

References
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 Aug;22(8):983-988. [Medline: 1866765]
2. Vanbeselaere V, Truyers C, Eilli S, Buntinx F, De Witte H, Degryse J, et al. Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study. BMC Cardiovasc Disord 2016 Mar 28;16:61 [FREE Full text] [doi: 10.1186/s12872-016-0235-1] [Medline: 27021333]
3. Santos JV, Pereira J, Pinto R, Castro PM, Azevedo E, Freitas A. Atrial Fibrillation as an Ischemic Stroke Clinical and Economic Burden Modifier: A 15-Year Nationwide Study. Value Health 2017 Sep;20(8):1083-1091 [FREE Full text] [doi: 10.1016/j.jval.2017.04.018] [Medline: 28964440]
4. Johnsen SP, Dalby LW, Tickström T, Olsen J, Fraschke A. Cost of illness of atrial fibrillation: a nationwide study of societal impact. BMC Health Serv Res 2017 Nov 10;17(1):714 [FREE Full text] [doi: 10.1186/s12913-017-2652-y] [Medline: 29126415]
5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016 Oct 07;37(38):2893-2962. [doi: 10.1093/eurheartj/ehw210] [Medline: 27567408]
6. Hald J, Poulsen PB, Qvist I, Holm L, Wedell-Wedellsborg D, Dybro L, et al. Opportunistic screening for atrial fibrillation in a real-life setting in general practice in Denmark-The Atrial Fibrillation Found On Routine Detection (AFFORD) non-interventional study. PLoS One 2017;12(11):e0188086 [FREE Full text] [doi: 10.1371/journal.pone.0188086] [Medline: 29131836]
7. Welton NJ, McAleenan A, Thom HH, Davies P, Hollingworth W, Higgins JP, et al. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis. Health Technol Assess 2017 May;21(29):1-236 [FREE Full text] [doi: 10.3310/hta21290] [Medline: 28629510]
8. Primo J, Gonçalves H, Macedo A, Russo P, Monteiro T, Guimarães J, et al. Prevalence of paroxysmal atrial fibrillation in a population assessed by continuous 24-hour monitoring. Rev Port Cardiol 2017;36(7-8):535-546 [FREE Full text] [doi: 10.1016/j.repc.2016.11.005] [Medline: 28709762]
9. Turakhia MP, Shafirin J, Bognar K, Trocio J, Abdulsattar Y, Wiederkehr D, et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS One 2018;13(4):e0195088 [FREE Full text] [doi: 10.1371/journal.pone.0195088] [Medline: 29649277]
10. Hobbs FDR, Fitzmaurice DA, Mant J, Murray E, Jewett S, Bryan S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9(40):iii-iv, ix [FREE Full text] [doi: 10.3310/hta9400] [Medline: 16202350]

11. De Ridder B, Van Rompaey B, Kampen JK, Haine S, Dilles T. Smartphone Apps Using Photoplethysmography for Heart Rate Monitoring: Meta-Analysis. JMIR Cardio 2018 Feb 27;2(1):e4 [FREE Full text] [doi: 10.2196/cardio.8802] [Medline: 31758768]

12. Jonathan E, Leahy M. Investigating a smartphone imaging unit for photoplethysmography. Physiol Meas 2010 Nov;31(11):N79-N83. [doi: 10.1088/0967-3334/31/11/N01] [Medline: 20871134]

13. Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. Circulation 2017 Nov 07;136(19):1784-1794. [doi: 10.1161/CIRCULATIONAHA.117.030583] [Medline: 28851729]

14. Chan N, Choy C. Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. Heart 2017 Jan 01;103(1):24-31. [doi: 10.1136/heartjn-2016-309993] [Medline: 27733533]

15. Li KHC, White FA, Tipoe T, Liu T, Wong MC, Jesuthasan A, et al. The Current State of Mobile Phone Apps for Monitoring Heart Rate, Heart Rate Variability, and Atrial Fibrillation: Narrative Review. JMIR Mhealth Uhealth 2019 Feb 15;7(2):e11606 [FREE Full text] [doi: 10.2196/11606] [Medline: 30767904]

16. Proesmans T, Mortelmans C, Van Haestl R, Verbrugge F, Vandervoort P, Vaes B. Mobile Phone-Based Use of the Photoplethysmography Technique to Detect Atrial Fibrillation in Primary Care: Diagnostic Accuracy Study of the FibrichCheck App. JMIR Mhealth Uhealth 2019 Mar 27;7(3):e12284 [FREE Full text] [doi: 10.2196/12284] [Medline: 30916656]

17. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc 2013 Mar 18;2(2):e000102 [FREE Full text] [doi: 10.1161/JAHA.112.000102] [Medline: 23537808]

18. Tocchi C, Dixon J, Naylor M, Jeon S, McCorkle R. Development of a frailty measure for older adults: the frailty index for elders. J Nurs Meas 2014;22(2):223-240. [doi: 10.1091/2016-1061-3749.22.22.223] [Medline: 25255675]

19. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 Jun;30(6):473-483. [Medline: 15939143]

20. Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9(40):iii-iv, ix [FREE Full text] [doi: 10.3310/hta9400] [Medline: 16202350]

21. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998 Nov;51(11):1055-1068. [doi: 10.1016/s0895-4356(98)00097-3] [Medline: 9817123]

22. Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open 2017 Sep;7(4):205031211774735 [FREE Full text] [doi: 10.1177/205031211774735] [Medline: 27752730]

23. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999 Sep;52(9):861-873. [doi: 10.1016/s0895-4356(99)00071-2] [Medline: 12587533]

24. Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007;7(5):541-546. [doi: 10.1016/j.spinee.2007.01.008] [Medline: 17448732]

25. Tarlov AR, Ware JE, Greenfield S, Nelson EC, Perrin E, Zuhkoff M. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989 Aug 18;262(7):925-930. [doi: 10.1001/jama.262.7.925] [Medline: 67097929]

26. Kruse C, Fohn J, Wilson N, Nunne Patlan E, Zipp S, Mileski M. Utilization Barriers and Medical Outcomes Commensurate With the Use of Telehealth Among Older Adults: Systematic Review. JMIR Med Inform 2020 Aug 12;8(8):e20359 [FREE Full text] [doi: 10.2196/20359] [Medline: 30767904]

27. Hendrix T, Hörnsten R, Rosenqvist M, Sandström H. Screening for atrial fibrillation with baseline and intermittent ECG recording in an out-of-hospital population. BMC Cardiovasc Disord 2013 Jun 10;13:41 [FREE Full text] [doi: 10.1186/1471-2261-13-41] [Medline: 23758799]

28. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213-220 [FREE Full text] [doi: 10.2147/CLEP.S47385] [Medline: 24966695]

29. Fischer SH, David D, Crotty BH, Dierks M, Safran C. Acceptance and use of health information technology by community-dwelling elders. Int J Med Inform 2014 Sep;83(9):624-635 [FREE Full text] [doi: 10.1016/j.ijmedinf.2014.06.005] [Medline: 24996581]
**SEM:** standard error of measurement